Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents

Iacobaeus, Ellen; Hopia, L; Khademi, Mohsen; Lundén, Mikaela; Al, Hammarin; Svenungsson, Elisabet; Andersson, Maria

doi:10.1177/0961203312470977

Cited by 5 publications

(3 citation statements)

References 86 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Iacobaeus et al showed that no JCV DNA could be detected in cerebrospinal fluid from SLE patients with neuropsychiatric manifestation. 17 We also did not find any correlations between the neuropsychiatric manifestations of SLE and the presence of JCV viruria or urine JCV viral load. On the other hand, we observed an unexpected result that the presence of JCV viruria in SLE patients was significantly associated with the occurrence of arthritis/arthralgia.…”

Section: Discussioncontrasting

confidence: 52%

Increased prevalence of JC polyomavirus viruria was associated with arthritis/arthralgia in patients with systemic lupus erythematosus

et al. 2014

Lupus

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 52%

Increased prevalence of JC polyomavirus viruria was associated with arthritis/arthralgia in patients with systemic lupus erythematosus

et al. 2014

Lupus

View full text Add to dashboard Cite

show abstract

“…Biologic therapies have successfully been introduced into the treatment of several inflammatory rheumatic diseases in particular, monoclonal antibodies or fusion proteins targeting TNF-α are widely used for the treatment of CIRDs patients refractory to conventional immune-suppressive medications. Nevertheless, treatments with biological drugs are associated with an increased susceptibility to viral infections including that by JCPyV, the etiological agent of the demyelinating disease named PML (Comar et al, 2013 ; Iacobaeus et al, 2013 ). The incidence of PML in immune-mediated diseases has recently increased as a consequence of an improved use of biologics and other potent immune-modulatory medications (Berger, 2010 ).…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of PML in immune-mediated diseases has recently increased as a consequence of an improved use of biologics and other potent immune-modulatory medications (Berger, 2010 ). Few studies are present in literature that demonstrate a real risk of PML development in CIRDs patients whereas several researches have focused on a possible correlation between JCPyV viremia and the biological therapy in patients with multiple sclerosis (MS) and CD (Lavagna et al, 2007 ; Verbeeck et al, 2008 ; Bellizzi et al, 2011 , 2013a , b ; Bharat et al, 2012 ; Comar et al, 2013 ; Iacobaeus et al, 2013 ; Tur et al, 2013 ; Frohman et al, 2014 ). Therefore, it could be interesting to understand whether there is a correlation between biologics administered for CIRDs and the opportunity that the virus escapes from latency, replicates actively and spreads to the brain causing PML.…”

Section: Discussionmentioning

confidence: 99%

Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study

et al. 2016

View full text Add to dashboard Cite

Chronic inflammatory rheumatic diseases (CIRDs) are immune-mediated pathologies involving joints. To date, TNFα-blocking agents administration is the most promising therapy, although these treatments are associated with an increased Polyomavirus JC (JCPyV) reactivation, the etiological agent of the Progressive Multifocal Leukoencephalopathy (PML). The aim of this study was the recruitment and the analysis of a CIRDs cohort in order to investigate a possible correlation between JCPyV presence and the influence of anti-TNF-α agents on viral loads. Blood and urine samples were collected from 34 CIRDs subjects prior the first anti-TNF-α infusion (T0) and after 3 (T3), 6 (T6), 12 (T12), and 18 (T18) months. Results showed persistent JC viruria significantly higher than JC viremia throughout the 18 month follow-up study (p = 0.002). In JCPyV positive samples, the non-coding control region (NCCR) was analyzed. Results evidenced archetypal structures (type II-S) in all isolates with the exception of a sequence isolated from a plasma sample, that corresponds to the type II-R found in PML subjects. Finally, the viral protein 1 (VP1) genotyping was performed and results showed the prevalence of the European genotypes 1A, 1B, and 4. Since only few studies have been carried out to understand whether there is a PML risk in CIRDs population infected by JCPyV, this study contributes to enrich literature insight on JCPyV biology in this cluster. Further investigations are necessary in order to recognize the real impact of biologics on JCPyV life cycle and to identify possible and specific viral variants related to increased virulence in CIRDs patients.

show abstract

Impact Analysis of Autoantibody Level and NR2 Antibody Level in Neuropsychiatric SLE Treated by Methylprednisolone Combined with MTX and DXM Intrathecal Injection

Wang

Zhao

Zhang

et al. 2014

Cell Biochem Biophys

View full text Add to dashboard Cite

The objective is to explore the clinical curative effects of methylprednisolone combined with MTX and DXM intrathecal injection in treating neuropsychiatric systemic lupus erythematosus (NPSLE) and its effects on autoantibody level and anti-N-methyl-D-aspartate receptor subtype NR2a/2b antibody (anti-NR2 antibody) level. Thirty six admitted NPSLE patients were treated by methylprednisolone combined with MTX and DXM intrathecal injection. Thirty six SLE patients without neuropsychiatric symptoms were selected as non-NPSLE group. Clinical indexes including SLE activity index, erythrocyte sedimentation rate (ESR), cerebrospinal fluid pressure (CSFP), cerebrospinal fluid protein were observed before and after treatment. Autoantibodies including anti-nuclear antibody (ANA), anti-double stranded DNA antibody (anti-dsDNA antibody), anti-extractable nuclear antigen antibody (ENA-Ab) were detected before and after treatment. Enzyme linked immunosorbent assay was used to detect NR2 antibody level before and after treatment in two groups. Upon treatment of methylprednisolone combined with MTX and DXM intrathecal injection, SLE activity index, ESR, CSFP, cerebrospinal fluid protein of 36 NPSLE patients were significantly decreased. Before treatment, positive rates of ANA, anti-dsDNA antibody, and anti-ENA antibody in both NPSLE group and non-NPSLE group had no significant difference. However, positive rate of anti-NR2 antibody in NPSLE group was significantly higher than that of non-NPSLE group. After treatment, positive rates of autoantibodies and anti-NR2 antibody in both NPSLE and non-NPSLE group were significantly decreased. Anti-NR2 antibody can be a screening index of NPSLE, and methylprednisolone combined with MTX and DXM intrathecal injection has significant curative effects and can effectively decrease autoantibody level and anti-NR2 antibody level.

show abstract

Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents

Abstract: JCV DNA was absent in CSF and plasma in NPSLE patients and controls and consequently we were not able to identify any correlation between the occurrence of JCV DNA and type of immunosuppressive medication.

Cited by 5 publications

References 86 publications

Increased prevalence of JC polyomavirus viruria was associated with arthritis/arthralgia in patients with systemic lupus erythematosus

Increased prevalence of JC polyomavirus viruria was associated with arthritis/arthralgia in patients with systemic lupus erythematosus

Increased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study

Impact Analysis of Autoantibody Level and NR2 Antibody Level in Neuropsychiatric SLE Treated by Methylprednisolone Combined with MTX and DXM Intrathecal Injection

Contact Info

Product

Resources

About